Summary
123.57 0.17(0.13%)09/16/2024
BioNTech SE (BNTX)
BioNTech SE (BNTX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.13 | 22.95 | 45.00 | 39.70 | 32.88 | 13.32 | 0.00 | 767.73 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 123.57 | |
| Open | 121.77 | |
| High | 129.38 | |
| Low | 120.95 | |
| Volume | 3,629,204 | |
| Change | 0.16 | |
| Change % | 0.13 | |
| Avg Volume (20 Days) | 1,421,516 | |
| Volume/Avg Volume (20 Days) Ratio | 2.55 | |
| 52 Week Range | 76.53 - 129.38 | |
| Price vs 52 Week High | -4.49% | |
| Price vs 52 Week Low | 61.46% | |
| Range | 1.47 | |
| Gap Up/Down | -3.63 | |
Fundamentals | ||
| Market Capitalization (Mln) | 29,352 | |
| EBIDTA | 10,294,551,552 | |
| PE Ratio | 8.7891 | |
| PEG Ratio | 0.0648 | |
| WallStreet Target Price | 317.35 | |
| Book Value | 35.6490 | |
| Earnings Per Share | 31.4900 | |
| EPS Estimate Current Quarter | 12.2700 | |
| EPS Estimate Next Quarter | 10.2700 | |
| EPS Estimate Current Year | 41.4800 | |
| EPS Estimate Next Year | 40.6000 | |
| Diluted EPS (TTM) | 31.4900 | |
| Revenues | ||
| Profit Marging | 0.5434 | |
| Operating Marging (TTM) | 0.7425 | |
| Return on asset (TTM) | 0.8162 | |
| Return on equity (TTM) | 1.5547 | |
| Revenue TTM | 13,789,625,344 | |
| Revenue per share TTM | 56.5910 | |
| Quarterly Revenue Growth (YOY) | 89.1820 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -222,037,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 8.7891 | |
| Forward PE | 7.5529 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.3235 | |
| Revenue Enterprise Value | 4.3592 | |
| EBITDA Enterprise Value | 5.6696 | |
| Shares | ||
| Shares Outstanding | 242,516,992 | |
| Shares Float | 77,885,077 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 66.88 | |
| Institutions (%) | 17.20 | |
09/13 18:52 EST - youtube.com
Trade It or Fade It: The week's big biotech moves
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
Trade It or Fade It: The week's big biotech moves
Jared Holz, Mizuho, joins 'Fast Money' to talk his playbook on recent biotech movers.
09/13 10:36 EST - zacks.com
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
09/11 07:20 EST - seekingalpha.com
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ivonescimab. Despite declining Covid-19 vaccine revenue and safety concerns about those shot, BioNTech's low valuation and promising pipeline make it a buy for risk-tolerant, long-term investors.
09/05 07:15 EST - globenewswire.com
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches.
BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) Congress 2024 in Barcelona, Spain from September 13-17, 2024. The oral and poster presentations will feature programs across BioNTech's clinical pipeline, including mRNA-based cancer vaccines, next-generation immunomodulators and targeted therapy approaches.
08/25 13:30 EST - globenewswire.com
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials Initiated
Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research
BioNTech BNT116 Lung Cancer mRNA Vaccine Clinical Trials Initiated
Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research Currently More Than 5 Lung Cancer Vaccines Based On mRNA Platform Are Under Clinical Trials Says Kuick Research
08/23 11:55 EST - seekingalpha.com
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.
Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab
Genmab's stock continues to struggle despite the strong progress of the company's commercial portfolio in the first half of the year. Epkinly is now FDA-approved for third-line+ follicular lymphoma, which should boost its revenue growth rates in the following quarters. BioNTech gave up on co-development of acasunlimab, but Genmab is undeterred and expects to start a phase 3 trial by the end of the year.
08/22 19:29 EST - news.sky.com
Lung cancer patient is first in UK to receive experimental vaccine
A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
Lung cancer patient is first in UK to receive experimental vaccine
A lung cancer patient has become the first in the UK to receive a new experimental vaccine to help his body fight the disease.
08/22 14:15 EST - globenewswire.com
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
NEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies' Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season's vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses.
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
NEW YORK and MAINZ, GERMANY, August 22, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA)), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies' Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. This season's vaccine is for use as a single dose for most individuals 5 years of age and older. Individuals 5 years of age and older with certain kinds of immunocompromise previously vaccinated with Pfizer and BioNTech COVID-19 vaccines or children under the age of 5 who have not already completed a three-dose series with previous formulas of a COVID-19 vaccine may be eligible to receive additional doses.
08/20 17:26 EST - seekingalpha.com
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Libtayo, for the treatment of patients with anti-PD-1/anti-PD-L1 relapsed/refractory or unresectable stage III or IV melanoma, met with statistical significance. Positive results obtained from an open-label phase 2 study, using BNT311 + Keytruda for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer; 12-month overall-survival [OS] rate of 69%.
BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
Partial clinical hold of BioNTech SE's BNT326/YL202 for the treatment of patients with solid tumors in phase 1 study was lifted by the FDA. The primary endpoint of ORR of BNT111 in combination with Libtayo, for the treatment of patients with anti-PD-1/anti-PD-L1 relapsed/refractory or unresectable stage III or IV melanoma, met with statistical significance. Positive results obtained from an open-label phase 2 study, using BNT311 + Keytruda for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer; 12-month overall-survival [OS] rate of 69%.
08/19 06:59 EST - reuters.com
BioNTech says FDA lifts partial hold on its cancer drug trial
BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
BioNTech says FDA lifts partial hold on its cancer drug trial
BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.
08/19 04:07 EST - fool.com
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve non-inferiority when compared to an approved flu vaccine.
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve non-inferiority when compared to an approved flu vaccine.
08/16 14:28 EST - investopedia.com
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined COVID-19 and flu vaccine in adults.
Pfizer, BioNTech Combination Flu and COVID-19 Shot Misses 1 of 2 Endpoints
Shares of Pfizer (PFE) and American depositary receipts (ADRs) of BioNTech (BNTX) dropped in intraday trading Friday following disappointing results from a late-stage study of the drugmakers' combined COVID-19 and flu vaccine in adults.
08/16 07:01 EST - marketwatch.com
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed “comparable” responses against the SARS-CoV-2 virus when compared with their licensed COVID-19 vaccine, which was one objective.
Pfizer, BioNTech COVID-19-flu combination drug meets 1 of 2 trial objectives
Pfizer Inc. PFE, -0.59% and BioNTech SE BNTX, +2.83% said Friday a Phase 3 trial of their COVID-19-influenza vaccine candidate met one of its two objectives. The companies said the candidate showed “comparable” responses against the SARS-CoV-2 virus when compared with their licensed COVID-19 vaccine, which was one objective.
08/16 06:51 EST - reuters.com
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.
Pfizer, BioNtech say combined flu-COVID vaccine misses a main goal of Phase 3 trial
Pfizer and BioNTech said a late-stage trial of their experimental mRNA vaccine to protect against influenza and COVID-19 found the combination shot failed to meet one of the study's two main goals and they are evaluating next steps.
08/16 06:45 EST - globenewswire.com
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer's mRNA-based influenza vaccine candidate with the companies' licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met. In a separate Phase 2 trial, Pfizer evaluated trivalent (“tIRV”) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
NEW YORK and MAINZ, Germany, August 16, 2024 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies' combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer's mRNA-based influenza vaccine candidate with the companies' licensed COVID-19 vaccine. The Phase 3 trial measured two primary immunogenicity objectives (immunogenicity against SARS-CoV-2 as well as immunogenicity against influenza A and B), of which one was met. In a separate Phase 2 trial, Pfizer evaluated trivalent (“tIRV”) influenza mRNA standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. The companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza B and will discuss next steps with health authorities.
08/08 06:40 EST - investorplace.com
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people's lives for the better.
08/06 11:04 EST - seekingalpha.com
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times.
BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
BioNTech SE reported Q2 2024 earnings yesterday, with a significant decrease in revenues from Comirnaty compared to previous years. The company reaffirmed guidance for 2024, for revenues of $2.7bn — $3.4bn, but is expecting a loss-making year due to increased costs. The cash position remains healthy at nearly $20bn, which helps to support a $19.5bn market cap valuation at the present times.
08/05 13:03 EST - seekingalpha.com
BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Tazeen Ahmad - Bank of America Securities Etzer Darout - BMO Capital Markets Yifeng Liu - HSBC Bank Plc Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Chris Shibutani - Goldman Sachs Simon Baker - Redburn Atlantic Eliana Merle - UBS John Newman - Canaccord Genuity Manos Mastorakis - Deutsche Bank Operator Welcome to BioNTech's Second Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
BioNTech SE (BNTX) Q2 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2024 Earnings Conference Call August 5, 2024 8:00 AM ET Company Participants Victoria Meissner - Vice President, Strategy & Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Tazeen Ahmad - Bank of America Securities Etzer Darout - BMO Capital Markets Yifeng Liu - HSBC Bank Plc Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Chris Shibutani - Goldman Sachs Simon Baker - Redburn Atlantic Eliana Merle - UBS John Newman - Canaccord Genuity Manos Mastorakis - Deutsche Bank Operator Welcome to BioNTech's Second Quarter 2024 Earnings Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.
08/05 10:46 EST - investopedia.com
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
American depositary receipts (ADRs) of BioNTech (BNTX) fell Monday after the COVID-19 vaccine maker's second-quarter loss quadrupled on falling demand for the shots, and as it ended an agreement with biotech firm Genmab to develop a lung cancer drug.
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
American depositary receipts (ADRs) of BioNTech (BNTX) fell Monday after the COVID-19 vaccine maker's second-quarter loss quadrupled on falling demand for the shots, and as it ended an agreement with biotech firm Genmab to develop a lung cancer drug.